MCA
ARQT icon

McGuire Capital Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

McGuire Capital Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$13.4K Hold
510
– – 0.01% 384
2026
Q1 		$12K Hold
510
– – 0.01% 369
2025
Q4 		$14.8K Buy
+510
New +$13.1K 0.01% 352

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

McGuire Capital Advisors's ARQT Position: Q2 2026 in Review

McGuire Capital Advisors held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 510 shares worth $13.4K. The position accounts for 0.01% of the portfolio, ranked #384.

McGuire Capital Advisors first reported a position in ARQT in Q4 2025 and has held it in 3 quarters since. The position peaked at $14.8K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • McGuire Capital Advisors held 510 shares of Arcutis Biotherapeutics worth $13.4K as of Q2 2026.
  • McGuire Capital Advisors left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up 0.01% of McGuire Capital Advisors's portfolio in Q2 2026, its #384 holding.
  • McGuire Capital Advisors first reported a position in Arcutis Biotherapeutics in Q4 2025 and has held it in 3 quarters since.
  • McGuire Capital Advisors's Arcutis Biotherapeutics position peaked at $14.8K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on McGuire Capital Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.